Verastem prices $250M offering, shares jump 20%
What's the deal? VerastemDealroom has a profile for this one. Try Dealroom →, a US biopharmaceutical company, priced an underwritten securities offering expected to raise roughly $250 million in gross proceeds. Shares rose about 20% in premarket trading on Wednesday after the announcement, which also included a CEO transition.
The details: The company priced 30,937,500 shares of common stock at $8.00 each, alongside pre-funded warrants. The post-IPO equity raise trades on Nasdaq under the ticker VSTM.
Why it stands out? At $250 million, the deal ranks among the largest post-IPO equity rounds for US health companies, landing in the 93rd percentile of such raises in a sample of 3,834 deals.
The signal: Large follow-on offerings give listed biopharma firms fresh capital without waiting for new investor rounds. For Verastem, the raise arrives alongside a leadership change — a combination that drew a sharp positive market reaction.
Read more: seekingalpha.com
Image credit: foteih
